Distinct Effects of Non-absorbed Agents Rifaximin and Berberine on the Microbiota-Gut-Brain Axis in Dysbiosis-induced Visceral Hypersensitivity in Rats

Berberine ameliorates ovariectomy-induced anxiety-like behaviors by enrichment in equol generating gut microbiota

(2021) Yuan Fang et al.   PHARMACOLOGICAL RESEARCH

Berberine alleviates visceral hypersensitivity in rats by altering gut microbiome and suppressing spinal microglial activation

(2021) Jin-dong Zhang et al.   ACTA PHARMACOLOGICA SINICA

Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study

(2021) Jie Ming et al.   Genome Medicine

Bacterial Peptidoglycan as a Driver of Chronic Brain Inflammation

(2020) Jon D. Laman et al.   TRENDS IN MOLECULAR MEDICINE

Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study

(2020) Ying-Xuan Chen et al.   Lancet Gastroenterology & Hepatology

Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome

(2020) Ying Li et al.   PHARMACOLOGICAL RESEARCH

Modulation of gut microbiota mediates berberine‐induced expansion of immuno‐suppressive cells to against alcoholic liver disease

(2020) Sha Li et al.   Clinical and Translational Medicine

Irritable bowel syndrome

(2020) Alexander C Ford et al.   LANCET

Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)

(2020) Yifei Zhang et al.   Nature Communications

Gut Microbiota in Patients With Irritable Bowel Syndrome—A Systematic Review

(2019) Rapat Pittayanon et al.   GASTROENTEROLOGY

The role of short-chain fatty acids in microbiota–gut–brain communication

(2019) Boushra Dalile et al.   Nature Reviews Gastroenterology & Hepatology

Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota

(2018) Yu Jin et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Irritable Bowel Syndrome

(2017) Alexander C. Ford et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice

(2017) Giada De Palma et al.   Science Translational Medicine

Activation of corticotropin-releasing factor neurons and microglia in paraventricular nucleus precipitates visceral hypersensitivity induced by colorectal distension in rats

(2016) Gongliang Zhang et al.   BRAIN BEHAVIOR AND IMMUNITY

Similar Fecal Microbiota Signatures in Patients With Diarrhea-Predominant Irritable Bowel Syndrome and Patients With Depression

(2016) Yixuan Liu et al.   Clinical Gastroenterology and Hepatology

Rome IV—Functional GI Disorders: Disorders of Gut-Brain Interaction

(2016) Douglas A. Drossman et al.   GASTROENTEROLOGY

The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review

(2016) Ami D Sperber et al.   GUT

Effects of Rifaximin on Transit, Permeability, Fecal Microbiome and Organic Acid Excretion in Irritable Bowel Syndrome

(2016) Andrés Acosta et al.   Clinical and Translational Gastroenterology

Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea

(2015) M. Pimentel   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Mo1268 Characterization of Stool Microbiota in Subjects With IBS-D Receiving Repeat Treatments With Rifaximin in the TARGET 3 Study

(2015) Mark Pimentel et al.   GASTROENTEROLOGY

Host microbiota constantly control maturation and function of microglia in the CNS

(2015) Daniel Erny et al.   NATURE NEUROSCIENCE

A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome

(2015) Chunqiu Chen et al.   PHYTOTHERAPY RESEARCH

The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism

(2014) Gary Frost et al.   Nature Communications

Rifaximin Alters Intestinal Bacteria and Prevents Stress-Induced Gut Inflammation and Visceral Hyperalgesia in Rats

(2013) Dabo Xu et al.   GASTROENTEROLOGY

Inflammasome induction in Rasmussen’s encephalitis: cortical and associated white matter pathogenesis

(2013) Vijay Ramaswamy et al.   Journal of Neuroinflammation

The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota

(2013) L. Crouzet et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Altered brain activation to colorectal distention in visceral hypersensitive maternal-separated rats

(2012) M. M. Wouters et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

(2011) Mark Pimentel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regional Gray Matter Density Changes in Brains of Patients With Irritable Bowel Syndrome

(2010) David A. Seminowicz et al.   GASTROENTEROLOGY

Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system

(2010) Simone Maccaferri et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Role of Spinal Microglia in Visceral Hyperalgesia and NK1R Up-Regulation in a Rat Model of Chronic Stress

(2008) Sylvie Bradesi et al.   GASTROENTEROLOGY